drugset / Trial / NCT06567119
Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects
Phase 1
Not yet recruiting
10 enrolled
SIPO Biotechnology Co. Ltd.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.
Timeline
- Start
- 2027-01-11
- Primary completion
- 2029-01-12
- Completion
- 2029-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SPOT-mRNA01 | Messenger RNA (mRNA) | — | Subcutaneous |